Austar Lifesciences Limited board of directors announced that the group is expected to record a substantial reduction of not less than 60% in consolidated profits attributable to the shareholders of the company for the six months ending June 30, 2015, as compared with the corresponding period in 2014, mainly attributable to: delay in recognition of revenue due to subsequent modification of users requirements for projects undertaken by the Group during the past few months; and decrease in gross profit margin for certain projects undertaken by the Group.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.69 HKD | +1.47% |
|
0.00% | -55.77% |
03-26 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-22 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
1st Jan change | Capi. | |
---|---|---|
-55.77% | 45.3M | |
-5.60% | 181B | |
-4.45% | 101B | |
-4.15% | 67.54B | |
-8.63% | 45.09B | |
+9.70% | 44.37B | |
+6.13% | 40.7B | |
+15.22% | 29.85B | |
+14.80% | 24.49B | |
-6.46% | 23.99B |
- Stock Market
- Equities
- 6118 Stock
- News Austar Lifesciences Limited
- Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ending June 30, 2015